How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    Draft Guidance for HTE10063 Digital technologies to support self-management of asthma

    Open for comments Open until   Request commenting lead permission

    We have updated this service so that members of the same organisation can now collaborate on a joint online response.

    Read our blog to learn more.

    1 Guidance development process

    NICE early-use HealthTech guidance provides recommendations on promising health technologies that have the potential to address national unmet need. NICE has assessed early evidence on these technologies to determine if earlier patient and system access in the NHS is appropriate while further evidence is generated.

    Early-use HealthTech guidance recommendations are conditional while more evidence is generated to address uncertainty in their evidence base. NICE has included advice in this guidance on how to minimise any clinical or system risk of early access to treatment.

    Further evidence will be generated over the next 3 years to assess if the benefits of these technologies are realised in practice. NICE guidance will be reviewed to include this evidence and make a recommendation on the routine adoption of this technology across the NHS.

    Find out more in the section on early-use HealthTech guidance assessments in NICE's HealthTech programme manual.

    NICE is producing this guidance on digital technologies to support self-management of asthma in the NHS in England. The medical technologies advisory committee has considered the evidence and the views of clinical and patient experts.

    This document has been prepared for consultation with the stakeholders. It summarises the evidence and views that have been considered, and sets out the recommendations made by the committee. NICE invites comments from the stakeholders for this evaluation and the public. This document should be read along with the evidence.

    The committee is interested in receiving comments on the following:

    • Has all of the relevant evidence been taken into account?

    • Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

    • Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

    After consultation:

    • Based on the consultation comments received, the committee may meet again.

    • If committee meets again it will consider the evidence, this evaluation consultation document and comments from stakeholders.

    • The committee will then prepare the final draft guidance, which will go through a resolution process before the final guidance is agreed.

    Note that this document is not NICE's final guidance on digital technologies to support self-management of asthma. The recommendations in section 1 may change after consultation.

    More details are available in NICE's HealthTech programme manual.

    Key dates

    Closing date for comments: 21 January 2026

    Second committee meeting: 19 February 2026